Skip to main content

Table 2 Final pharmacokinetic and pharmacodynamic model parameters

From: Model-based assessment of the safety of community interventions with primaquine in sub-Saharan Africa

Parameter

Estimate

RSE+, CV%

VPQ, l (70 kg)

130

6.05

CLH1, l/h (70 kg)

25.1

8.78

CLH2, l/h (70 kg)

5.6

29.6

MAT, h

0.915

11.2

IIV CL#, CV%

46

30.6

IIV VPQ, CV%

44

26.5

IIV MAT, CV%

55

28.8

Proportional error, %

25.3

20.0

Additive error, ng/mla

2

Lifespan, h

276

50

Slope, CCYP2D6−1·h−1

0.0012

49

FG6PDd

2.46

103

Proportional error Hb, V%

6.95

4

  1. CCYP2D6: concentration in the compartment for CYP2D6-mediated metabolites; CLH1: hepatic clearance out of the system; CLH2: CYP2D6-mediated hepatic clearance; CV: coefficient of variation; FG6PDd: factor by which the primaquine-induced elimination of erythrocytes is increased in G6PD-deficient individuals; IIV: inter-individual variability; MAT: mean absorption time; RSE: relative standard error; Slope: concentration-slope effect of primaquine-induced elimination of erythrocytes; VPQ: volume of distribution for primaquine
  2. +As derived from a non-parametric bootstrap with 1000 samples
  3. #Both CLH1 and CLH2 share the same inter-individual variability
  4. aParameter was fixed during parameter estimation